^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Hodgkin Lymphoma |
| Drug: | Tyvyt (sintilimab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Safety and clinical efficacy of sintilimab in pediatric patients with advanced or recurrent malignancies in a phase I study.
Published date:
05/25/2023
Excerpt:
29 patients were enrolled, including 10 patients with Hodgkin lymphoma (HL), 19 patients with other tumor types...Sintilimab was well tolerated without dose-limiting toxicity...Subjects with PD-L1-positive expression benefited more from sintilimab treatment than PD-L1-negative subjects (66.7% ORR versus 33.3% ORR, p=0.314)...Sintilimab was well tolerated and demonstrated promising anti-tumor activity in pediatric HL.
DOI:
10.1200/JCO.2023.41.16_suppl.e14601
Trial ID:
